It's still true today, although the opportunities go beyond the ubiquitous fast food icons that have dominated the realm of franchises since the 1970s.
David Jackson, 59, of Moonville, S.C., found his niche in the packing and shipping business, as owner of a Goin' Postal franchise.
Grandson of a sharecropper, Jackson retired early from his job of 36 years as a supervisor at a Michelin Tire plant because he wanted to interact with the public and serve his community.
"I wanted to do something different with my life," he says. "I've been living in this community for 30-plus years and had seen a need for something like this."
5 Best Canadian Stocks To Invest In Right Now: Forest Laboratories Inc (FRX)
Forest Laboratories, Inc. (Forest), incorporated on April 11, 1956, develops, manufactures and sells branded forms of ethical drug products, most of which requires a physician's prescription. The Company also focuses on the development and introduction of new products, including products developed in collaboration with licensing partners. Its products include those developed by the Company and those acquired from other pharmaceutical companies and integrated into its marketing and distribution systems. The Company�� principal products include Lexapro, its selective serotonin reuptake inhibitor (SSRI) for the treatment of major depressive disorder (MDD) in adults and adolescents and generalized anxiety disorder (GAD) in adults; Namenda, its N-methyl-D-Aspartate (NMDA) antagonist for the treatment of moderate and severe Alzheimer's disease; Bystolic, its beta-blocker for the treatment of hypertension; Savella, its selective serotonin and norepinephrine reuptake inhibitor (SNRI) for the management of fibromyalgia and its newest marketed product Teflaro, a broad-spectrum hospital-based injectable cephalosporin antibiotic for the treatment of adults with community-acquired bacterial pneumonia. On April 13, 2011, the Company acquired Clinical Data Inc. (Clinical Data), a specialty pharmaceutical company.
Aclidinium
In June 2011, the Company ahs submitted a New Drug Application (NDA) to the Food and Drug Administration (FDA) for aclidinium (aclidinium bromide), a long-acting antimuscarinic agent developed as an inhaled therapy for the maintenance treatment of chronic obstructive pulmonary disease (COPD). When given by inhalation, aclidinium leads to bronchodilation by inhibiting airway smooth muscle contraction. Aclidinium is rapidly hydrolyzed in human plasma to two major inactive metabolites. Aclidinium is administered to patients using a multi-dose dry powder inhaler (MDPI). This inhaler was designed with a feedback system which, through a ��olored control window��and an a! udible click, helps confirm that the patient has inhaled correctly. It contains multiple doses of aclidinium, includes a visible dose-level indicator, and also incorporates features such as an anti-double dosing mechanism and an end-of-dose lock-out system to prevent use of an empty inhaler.
Linaclotide
Linaclotide is being investigated for the treatment of constipation-predominant irritable bowel syndrome (IBS-C) and chronic constipation (CC). Linaclotide is an agonist of the guanylate cyclase type-C receptor found in the intestine and acts by a mechanism. Linaclotide increases fluid secretions leading to increased bowel movement frequency and reduces abdominal pain. Linaclotide is administered orally but acts locally in the intestine with no measurable systemic exposure at therapeutic doses and is intended for once-daily administration.
Viibryd
As a result of its acquisition of Clinical Data, Inc. (Clinical Data) completed in April 2011, the Company obtained worldwide rights to develop and market Viibryd (vilazodone HCl) a selective serotonin reuptake inhibitor and a 5-HT1A receptor partial agonist developed by Clinical Data for the treatment of adults with major depressive disorder (MDD). Viibryd became available to patients during the June 2011 quarter and was formally launched in the U.S. in late August 2011.
Daliresp
In February 2011, the Company received approval from the United States Food and Drug Administration (FDA) for the marketing of Daliresp (roflumilast). Daliresp is once-daily, orally administered, selective phosphodiesterase 4 (PDE4) enzyme inhibitor, developed by its partner, Nycomed GmbH (Nycomed), as a treatment to reduce the risk of exacerbations in patients with severe chronic obstructive pulmonary disease (COPD) associated with chronic bronchitis and a history of exacerbations.
Namenda
Namenda (memantine HCl) is an N-methyl-D-Aspartate (NMDA) receptor agonist for the treatmen! t of mode! rate and severe Alzheimer�� disease. In June 2010, Namenda XR was approved by the FDA for the treatment of moderate to severe dementia of the Alzheimer�� type. Namenda XR is a 28 milligrams once-daily extended-release formulation of Namenda. The Company has obtained the exclusive rights to develop and market memantine in the United States by license agreement with Merz Pharma GmbH & Co. KgaA (Merz) of Germany, the originator of the product.
Bystolic
Bystolic is a beta-1 selective beta-blocker with vasodilating properties. Bystolic decreases heart rate and myocardial contractility and suppresses rennin activity. The Company licensed exclusive United States and Canadian rights to Bystolic from Mylan Inc. (Mylan).
Savella
Savella (milnacipran HCl) is the Company�� selective serotonin and norepinephrine inhibitor (SNRI) for the management of fibromyalgia. Fibromyalgia is a chronic condition characterized by widespread pain and decreased physical function. The Company licensed the United States and Canadian rights to develop and commercialize Savella from Cypress Bioscience, Inc. (Cypress). Its license agreement includes two patents covering the use of Savella for the management of fibromyalgia.
Teflaro
In October 2010, the Company received marketing approval from the FDA for Teflaro (ceftaroline) for the treatment of adults with community-acquired bacterial pneumonia, including cases caused by Streptococcus pneumoniae bacteremia and with acute bacterial skin and skin structure infections, including cases caused by methicillin-resistant Staphylococcus aureus. Teflaro is a spectrum, hospital-based injectable cephalosporin antibiotic with activity against Gram-positive bacteria and common Gram-negative bacteria. Teflaro is a member of the cephalosporin class of antibiotics. The worldwide rights (excluding Japan) to Teflaro are in-licensed on an exclusive basis from Takeda Pharmaceutical Company (Takeda). Teflaro is als! o covered! by two United States patents that relate to the ceftaroline formulation that expire in 2021 and that may provide additional exclusivity.
Avibactam
Avibactam is designed to be co-administered with select antibiotics to enhance their spectrum of activity. The Company received the exclusive rights to administer avibactam with ceftaroline as a combination product in North America. Avibactam is a beta-lactamase inhibitor designed to be co-administered with select antibiotics to enhance their spectrum of activity by overcoming beta-lactamase-related antibacterial resistance.
Lexapro
Lexapro�� is a SSRI for the treatment of MDD in adults and adolescents and GAD in adults. Lexapro�� (escitalopram oxalate) single isomer version of citalopram HBr, for the treatment of MDD in adults and adolescents and GAD in adults.
Cariprazine
Cariprazine is an oral D2/D3 partial agonist. Cariprazine is also undergoing Phase III trials for schizophrenia and acute mania associated with bipolar depression, bipolar depression and as an adjunct treatment for MDD.
Levomilnacipran
Levomilnacipran is a once-daily, selective norepinephrine and serotonin reuptake inhibitor, two neurotransmitters known to play an essential role in regulating mood, and is being developed for the treatment of MDD.
GRT 6005
In December 2010, the Company entered into a license agreement with Grunenthal GmbH for the co-development and commercialization of GRT 6005 and its follow-on compound GRT 6006, small molecule analgesic compounds being developed by Grunenthal for the treatment of moderate to severe chronic pain. GRT 6005 and GRT 6006 are compounds with pharmacological and pharmacokinetic profiles that may enhance their effect in certain pain conditions. GRT 6005 has completed initial proof-of-concept studies in nociceptive and neuropathic pain with further Phase II studies planned prior to initiation of Phase III s! tudies.
TTP399
In June 2010, the Company entered into a license agreement with TransTech Pharma, Inc. (TransTech) for the development and commercialization of TTP399, a functionally liver selective glucokinase activator (GKA) discovered and developed by TransTech for the treatment of Type II diabetes. Early Phase I testing suggests that pharmacological enhancement of glucokinase activity may lower blood glucose in diabetic patients.
Azimilide
In April 2011, the Company entered into an agreement with Blue Ash Therapeutics, LLC (Blue Ash) pursuant to which it acquired the worldwide rights to azimilide, a class III antiarrhythmic agent developed by Proctor & Gamble Pharmaceuticals. Based on its mechanism of action and results of clinical trials, azimilide was determined to be suited for use in patients with a history of life-threatening ventricular arrhythmias and who have an implantable cardioverter defibrillator. In 2010, the FDA agreed to one additional Phase III study to support a regulatory submission for azimilide in the U.S.
RGH-618
RGH-618 involves a series of compounds that target metabotropic glutamate receptors and are agonists, which represent potential agents for the treatment of anxiety, depression and other central nervous system (CNS) conditions. In March 2012, the Company initiated a Phase I study in healthy volunteers of RGH-618.
Advisors' Opinion:- [By Sean Williams]
So what: Take that phrase "better than expected" with a grain of salt, because when you're a growing biotechnology company with a newly approved drug, Wall Street tends to cut you some slack. For the quarter, Ironwood recorded a 34% decline in revenue to $9.7 million as its loss widened to $0.57 per share. Comparatively speaking, though, this was far better than the $0.70 loss per share on $6.2 million in revenue that the Street had expected. Furthermore, Ironwood backed its full-year sales and marketing expense guidance for its lead drug, Linzess, that it co-markets with Forest Laboratories (NYSE: FRX ) . According to Forest Labs, sales of the drug, which is used to treat irritable bowel syndrome with constipation and chronic idiopathic constipation in adults, totaled $28.8 million for the second quarter.
- [By Brian Marckx]
Several large pharma companies have OA drug candidates in various stages of clinical trials including GlaxoSmithKline (GSK), Abbott Laboratories (ABT), and Forest Laboratories (FRX) and would have potentially significant interest in a test such as ILIU's OA test.
5 Best Shipping Stocks To Own For 2014: Magellan Midstream Partners L.P.(MMP)
Magellan Midstream Partners, L.P., together with its subsidiaries, engages in the transportation, storage, and distribution of refined petroleum products and crude oil in the United States. Its pipeline system transports petroleum products and liquefied petroleum gases from the Gulf Coast refining region of Texas through the Midwest to Colorado, North Dakota, Minnesota, Wisconsin, and Illinois. The company owns and operates marine terminals, which store and distribute refined petroleum products, blendstocks, crude oils, heavy oils, and feedstocks, as well as inland terminals that consist of storage tanks connected to third-party interstate pipeline systems to deliver refined petroleum products. Its ammonia pipeline system transports ammonia from production facilities in Texas and Oklahoma to terminals in the Midwest. The company also stores, blends, and distributes biofuels, such as ethanol and biodiesel. As of March 31, 2011, it operated approximately 9, 600 miles of petr oleum products pipeline system and 51 terminals; 6 marine petroleum terminals located along the United States Gulf and East Coasts; a crude oil storage in Cushing, Oklahoma; 27 petroleum products inland terminals located principally in the southeastern United States; and a 1,100-mile ammonia pipeline system and 6 associated terminals. The company also provides ancillary services, such as heating, blending, and mixing of stored petroleum products and additive injection services. Its customers comprise independent and integrated oil companies, wholesalers, retailers, railroads, airlines, and regional farm co-operatives. The company serves various markets, including retail gasoline stations, truck stops, farm co-operatives, railroad fueling depots, and military and commercial jet fuel users. Magellan GP, LLC serves as the general partner of the company. The company was founded in 2000 and is based in Tulsa, Oklahoma.
Advisors' Opinion:- [By Arjun Sreekumar]
Magellan Midstream Partners (NYSE: MMP ) is thinking about expanding its newly reversed Longhorn pipeline, as demand for pipeline shipments from Texas' Permian Basin continues to grow.
- [By Tyler Crowe]
Perhaps bigger players like Occidental were able to hog the limited takeaway capacity, but this won't be a good reason for slowed production very soon. Magellan Midstream Partners (NYSE: MMP ) and DCP Midstream (NYSE: DCP ) both have pipelines coming on line within the next couple of months that will have takeaway capacity of 225,000 and 350,000 barrels per day, respectively. Once these pipelines come on line, there should be much more room for LINN's production.�
- [By WilliamBriat]
On September 17, Magellan Midstream Partners L.P. (NYSE: MMP) and El Paso Pipeline Partners, L.P. (NYSE: EPB) touched three-month lows while oil was still spiking near a two-year high. - [By Arjun Sreekumar]
Additionally, new and reversed pipelines are allowing more crude oil to flow directly from oil and gas hot spots, such as the Permian Basin of West Texas, to Gulf Coast refineries. For instance, Magellan Midstream Partners' (NYSE: MMP ) started up its reversed Longhorn pipeline in April, which provided another 225,000 barrels per day of incremental capacity from West Texas to Houston-area refineries, while Sunoco Logistics Partners (NYSE: SXL ) is expected to start up its Permian Express project this month, which will provide additional capacity out of the Permian Basin of about 90,000 barrels per day.
5 Best Shipping Stocks To Own For 2014: DiamondRock Hospitality Co (DRH)
DiamondRock Hospitality Company, incorporated on May 6, 2004, is a lodging-focused Maryland corporation operating as a real estate investment trust (REIT). It owns a portfolio of 27 premium hotels and resorts that contain 11,590 guest rooms. It also holds the senior note on a mortgage loan secured by an additional hotel and has the right to acquire, upon completion, a hotel under development. Its portfolio is concentrated in key gateway cities and destination resorts. Each of its hotels is managed by a third party and are operated under a brand owned by one of the global lodging brand companies (Marriott International, Inc. (Marriott), Starwood Hotels & Resorts Worldwide, Inc. (Starwood) or Hilton Worldwide (Hilton)). In November 2013, the Company sold the Torrance Marriott South Bay.
The Company conducts its business through an umbrella partnership REIT (UPREIT), in which its hotel properties are owned by its operating partnership, DiamondRock Hospitality Limited Partnership, or subsidiaries of its operating partnership. Its properties are concentrated in key gateway cities (primarily New York City, Chicago, Boston and Los Angeles) and in destination resort locations , such as the United States Virgin Islands and Vail, Colorado.
During the year ended December 31, 2012, it acquired five new hotels and sold four non-core hotels located in the markets: Atlanta, Georgia; Boston, Massachusetts ; Burlington, Vermont; Charleston, South Carolina; Chicago, Illinois ; Denver, Colorado ; Fort Worth, Texas; Los Angeles, California ; Minneapolis, Minnesota; New York, New York ; Oak Brook, Illinois; Orlando, Florida; Salt Lake City, Utah; San Diego, California; San Francisco, California; Sonoma, California; St. Thomas, U.S. Virgin Islands; Vail, Colorado and Washington, D.C. It also owns a senior mortgage loan secured by a 443-room hotel located in Chicago, Illinois and have the right to acquire, upon completion, a 282-room hotel under development in New York City.
On July ! 12, 2012, it acquired a portfolio of four hotels from affiliates of Blackstone Real Estate Partners VI. The portfolio consists of the Hilton Boston Downtown, Westin Washington D.C. City Center, Westin San Diego and Hilton Burlington. The portfolio consists of the 362-room Hilton Boston Downtown, the 406-room Westin Washington, D.C. City Center, the 436-room Westin San Diego and the 258-room Hilton Burlington. On November 9, 2012, it acquired the 94-room Hotel Rex located in San Francisco, California. On March 23, 2012, it completed the sale of a three-hotel portfolio. The portfolio consisted of the Griffin Gate Marriott Resort and Spa, the Renaissance Waverly, and the Renaissance Austin. On October 3, 2012, it completed the sale of the Atlanta Westin North at Perimeter.
The Oak Brook Hills Marriott Resort, the Orlando Airport Marriott and the Hilton Garden Inn Chelsea/New York City each failed its performance test at the end of 2012. The Bethesda Marriott Suites hotel is subject to a ground lease. The Courtyard Manhattan/Fifth Avenue is subject to a ground lease. The Salt Lake City Marriott Downtown is subject to two ground leases: one ground lease covers the land under the hotel and the other ground lease covers the portion of the hotel that extends into the City Creek Center. The Westin Boston Waterfront is subject to a ground lease. The Hilton Minneapolis is subject to a ground lease. In addition, the golf course that is part of the Oak Brook Hills Marriott Resort is subject to a ground lease covering approximately 110 acres. A portion of the parking garage relating to the Renaissance Worthington is subject to three ground leases that cover, contiguously with each other, approximately 1/4 of the land on which the parking garage is constructed. Furthermore, these ground leases generally require them to obtain and maintain insurance covering the subject property.
Advisors' Opinion:- [By Marc Bastow]
Lodging-focused real estate investment trust (REIT) DiamondRock (DRH) raised its dividend 21% to 10.25 cents per share, payable April 10 to shareholders of record as of March 31. Yielding more than 3%, DRH stock has the highest yield of this week’s dividend stocks increasing payouts.
DRH Dividend Yield: 3.38% - [By Laura Brodbeck]
Monday
Earnings Releases Expected: �McKesson�(NYSE: MCK), Concho Resources (NYSE: CXO), Diamondrock Hospitality (NYSE: DRH) Economic Releases Expected: �US Federal budget balance, Indian industrial productionTuesday
5 Best Shipping Stocks To Own For 2014: Pure Cycle Corporation(PCYO)
Pure Cycle Corporation, a vertically integrated water and wastewater service provider, engages in the design, construction, operation, and maintenance of water and wastewater systems in the Denver metropolitan area. The company contracts with landowners, developers, home builders, cities, and municipalities using a water portfolio consisting of surface and ground water supplies, surface and aquifer storage, and reclaimed water supplies. It withdraws, treats, stores, and delivers water to customers; collects, treats, stores, and reuses wastewater; and treats and delivers reclaimed water for irrigation use by customers. The company offers water services to approximately 258 single family equivalent (SFE) water connections, as well as 157 SFE wastewater connections located in southeastern metropolitan area of Denver. It has water assets in the Denver metropolitan area, Colorado; Arkansas River Valley in southern Colorado; and on the western slope of Colorado. The company was founded in 1976 and is based in Denver, Colorado.
Advisors' Opinion:- [By Garrett Cook]
On Wednesday, the utilities sector proved to be a source of strength for the market. Leading the sector was strength from Korea Electric Power (NYSE: KEP) and Pure Cycle (NASDAQ: PCYO).
- [By Jake L'Ecuyer]
Among the sector stocks, Pure Cycle (NASDAQ: PCYO) was down more than 1.3 percent, while Korea Electric Power (NYSE: KEP) tumbled around one percent.
No comments:
Post a Comment